Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
29 April 2022 - 1:01PM
Edgar (US Regulatory)
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of April 2022
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
AstraZeneca plans
new R&D centre in Massachusetts
29 April 2022 07:05 BST
AstraZeneca announces plans for new strategic R&D centre and
Alexion headquarters in Cambridge, Massachusetts
Move
brings together AstraZeneca and
Alexion colleagues in a purpose-built facility in Kendall Square,
Cambridge, MA, a world leading life sciences
hub
AstraZeneca today announced plans to open a new site at
the heart of the Cambridge, MA, life sciences and innovation
hub.
The new site will be a strategic R&D centre for AstraZeneca, as
well as Alexion's new corporate headquarters. The site
will bring together approximately 1,500 R&D, commercial
and corporate colleagues into a single purpose-built space in
Kendall Square, Cambridge, MA.
The site, scheduled for completion in 2026, will be in close
proximity to several major academic, pharma and biotech
institutions, inspiring greater collaboration and innovation
potential, and providing access to future talent. The move
reinforces AstraZeneca's
commitment to the greater Boston area, with over 570,000 square
feet of R&D and commercial space, and room for expansion for
the future.
Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "Today's
announcement is a milestone moment following the acquisition of
Alexion in July 2021. Our combined company has
already successfully leveraged internal scientific synergies,
and this move will act as a catalyst for even more external
collaboration and innovation.
"Kendall Square, Cambridge, is at the heart of the life sciences
and innovation hub of the greater Boston area, and our new site
will put us right at the centre of this space. The move will
provide access to some of the most innovative partners in
academia and biotech, offering opportunities to accelerate our
growth and collaborate with like-minded organisations as we
continue to push the boundaries of science to deliver advances for
patients."
Notes
AstraZeneca is working with BXP (NYSE:BXP) on development of the
new site.
In line with AstraZeneca's commitment to leading in sustainability,
the aim is for the new site to have platinum Leadership in Energy &
Environmental Design (LEED) certification, the highest level of
certification.
Alexion's R&D center of excellence will remain in New
Haven, Connecticut. Alexion recently signed a lease to expand
that campus as well, which will double Alexion's lab floor space in
New Haven by the end of 2023.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
29 April 2022
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Apr 2023 bis Apr 2024
